Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 3
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.
Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. Drago JZ, et al. Clin Cancer Res. 2019 Nov 1;25(21):6443-6451. doi: 10.1158/1078-0432.CCR-19-0138. Epub 2019 Aug 1. Clin Cancer Res. 2019. PMID: 31371343 Free PMC article.
The Harm in Kratom.
Drago JZ, Lane B, Kochav J, Chabner B. Drago JZ, et al. Oncologist. 2017 Aug;22(8):1010-1011. doi: 10.1634/theoncologist.2017-0279. Epub 2017 Jul 24. Oncologist. 2017. PMID: 28739869 Free PMC article.
A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer.
Jhaveri K, Drago JZ, Shah PD, Wang R, Pareja F, Ratzon F, Iasonos A, Patil S, Rosen N, Fornier MN, Sklarin NT, Chandarlapaty S, Modi S. Jhaveri K, et al. Among authors: drago jz. Clin Cancer Res. 2021 May 4:clincanres.0047.2021. doi: 10.1158/1078-0432.CCR-21-0047. Online ahead of print. Clin Cancer Res. 2021. PMID: 33947692